EDX Medical Group participating in “The Pub Test” Investor Evening

EDX Medical Group plc

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced its participation in “The Pub Test” Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at 6:00 PM.

The Company’s CEO, Dr Mike Hudson, will engage in a conversation designed especially for private investors. This informal setting offers an opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.

Commenting on the event, EDX Medical Group Dr Mike Hudson, said:

“We look forward to meeting and engaging with interested parties, shareholders, potential shareholders, and stakeholders, share our vision and answer any questions investors may have.”

All attendees will have the chance to network over drinks and a buffet.

To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers.

EDX Medical targets corporate health market with new screening service

EDX Medical is preparing to launch a corporate health screening service covering 14,000 employees, with testing expected to begin in Q4 2026.

EDX Medical positioned in growing prostate screening push

EDX Medical is positioned in the growing prostate screening debate as demand builds for more accurate, less invasive diagnostic testing.

EDX Medical Group deploys rapid pneumonia test at Addenbrooke’s ICU

EDX Medical Group has said its rapid pneumonia test is now in NHS clinical practice and has benefited patients at Addenbrooke's Hospital.

Professor Sir Chris Evans outlines EDX Medical’s new workplace health screening service

EDX Medical’s Chief Scientific Officer discusses the service’s on-site testing model, competitive advantages, employer demand and potential to generate more than £2 million this financial year.

EDX Medical launches BC95 bowel cancer testing service in the UK

EDX Medical Group has launched full UK availability of its BC95 bowel cancer biomarker testing service, combining early detection, hereditary risk analysis and a faecal haemoglobin reference test. The service reports sensitivity above 95% across all cancer stages and is designed to improve early diagnosis of colorectal cancer, which affects more than 46,000 people annually in the UK.

Search